CN110272870A - A kind of application of cell composition on cancer cell NCI-H1975 - Google Patents
A kind of application of cell composition on cancer cell NCI-H1975 Download PDFInfo
- Publication number
- CN110272870A CN110272870A CN201910404770.5A CN201910404770A CN110272870A CN 110272870 A CN110272870 A CN 110272870A CN 201910404770 A CN201910404770 A CN 201910404770A CN 110272870 A CN110272870 A CN 110272870A
- Authority
- CN
- China
- Prior art keywords
- cell
- cells
- culture
- gamma delta
- nci
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2312—Interleukin-12 (IL-12)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2318—Interleukin-18 (IL-18)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a kind of application of cell composition on cancer cell NCI-H1975, and in particular to the application of gamma delta T cells and NK cell composition on NCI-H1975.Gamma delta T and NK cell composition are obtained by co-culturing, inducing amplification method, gamma delta T is mixed and NK cytotoxicity/activity is strong, it is strong to the effect of NCI-H1975, almost therapeutic scheme can be provided for NCI-H1975 type cancer and disease with 100% killing NCI-H1975；The therapeutic process in clinic is simplified, treatment means are simplified, also reduces treatment cost.
Description
Technical field:
The present invention relates to field of biotechnology, and in particular to application of the immunocyte in disease is more particularly to cell
Application of the composition on cancer cell NCI-H1975.
Background technique:
Gamma delta T cells are that one kind can kill cancer cell, tumor stem cell, and can identify the immunocyte of cancer antigen.
Gamma delta T cells are the T cells for executing inherent immunity function, and TCR is made of γ and δ chain.Such T cell is mainly divided
It is distributed in the mucous membranes such as enteron aisle respiratory tract and urogenital tract and subcutaneous tissue, the 0.5%- of CD3+T cell is only accounted in peripheral blood
1%.Its TCR lack of diversity, can the certain complete polypeptide antigens of Direct Recognition.The antigen type that gamma delta T cells are identified has
Limit: 1. HSP；2. the lipid antigen of infection cell surface C D1 molecule deduction；3. certain virus proteins are expressed in infection cell table
The virus protein in face；4. the phosphorylation antigen in bacterial lysates.
Gamma delta T cells are that one kind can kill cancer cell, tumor stem cell, and can identify the immunocyte of cancer antigen, it
It is lethal relatively strong, but tumor stem cell killing is not so good as NK cell.Therefore, it is mainly used for killing cancer cell and DC cell is assisted to know
Not Fa Xian cancer cell antigen, these antigens are then killed or are passed to other cells.Meanwhile gamma delta T cells mainly divide
It is distributed on skin and mucous membrane tissue, therefore prominent for the treatment of cancer effect in terms of mucous membrane, such as alimentary canal, respiratory tract, life
Grow the cancer significant effect of system aspects.
Gamma delta T cells are mainly reached maturity in thymus gland, generate gamma delta T cells receptor (TCR) by V (D) J genetic recombination.
By the gene rearrangement of specificity, break up from a common lymphoid cell precursors (common lymphoidprecursor, CLP)
For the T cell system of express alpha beta receptor and γ δ receptor.The influence of missing, therefore γ δ are not processed vulnerable to antigen and presented to gamma delta T cells
T cell has very high clinical tumor immunization therapy potential using value.Gamma delta T cells are in cancer immunosurveillance and antitumor exempt from
It plays a significant role in epidemic disease reaction.
Gamma delta T cells effect is also embodied in:
1. gamma delta T cells can have an effect with panimmunity cell, anti-tumor immune response is participated in.
2. gamma delta T cells can cause rapidly effective antitumour immune response in tumorigenic early stage.
3. gamma delta T cells have important protective effect during antineoplastic immune.
4. gamma delta T can utilize cellulotoxic effect killing tumor cell, the occurrence and development of tumour are prevented.
5. gamma delta T cells can secrete correlation factor, these factors can amplify tumor signal.
6. gamma delta T cells can secrete perforin, inducing apoptosis of tumour cell.
Since content of the gamma delta T cells in peripheral blood is extremely low, greatly limits gamma delta T cells and exist as adoptive immunity cell
Application clinically.Gamma delta T cells are expanded from peripheral blood mononuclear cells at present, amplification times are low, and cell purity and cell concentration are not
It is high.The gamma delta T cells amplified are difficult to meet clinical demand, even if being amplified by optimizing various inductive conditions and amplification method
Single gamma delta T cells applied in corresponding immunity disease and tumor disease, but apply after and not up to people manage
Effect in thinking.
Cellular immunotherapy is one of current most promising oncotherapy mode, by returning after amplification in vitro or transformation
It is defeated to achieve the purpose that in patient body killing tumor cell or by activation body immune system, enhancing tumor patient itself exempt from
Epidemic disease function is to resist tumour or other diseases.Currently, NK cellular immunotherapy is more and more paid attention to.NK cell accounts for people
The 5-15% of peripheral blood lymphocytes, generally defining its phenotype is CD3-CD56+, and NK cell can be further subdivided into two again
Main subgroup: the CD56highCD16- cell with immunoloregulation function and the CD56dimCD16+ with cytotoxic activity
Cell.NK cell plays important immune surveillance function in viral infection resisting and antitumor early immune reaction, and NK is thin
Born of the same parents do not need identification tumour specific antigen, can directly, quickly play cytotoxic activity.Particularly importantly NK cell energy
Enough effectively intracorporal Multidrug-resistants of removing machine, inhibit the growth and transfer of tumour.
In existing research, single immunocyte or lethal cell is mostly used to carry out cell therapy or facing greatly
In bed treatment by the way of combination therapy, in the prior art, more costly expense is needed using combination therapy, be sufferer
Bring more economic pressures.
Therefore solving above-mentioned existing clinical picture is to be badly in need of.
Summary of the invention
For problem described above, the invention proposes a kind of application of cell composition on cancer cell NCI-H1975,
More particularly to gamma delta T cells and NK cell composition, application of the composition on NCI-H1975.
The cell composition includes: gamma delta T cells and NK cell.
The gamma delta T cells and NK cell proportion are 1:0.5-10.
Application of the above-mentioned cell mixture on cancer cell NCI-H1975.
Above-mentioned gamma delta T-NK cell composition preparation method:
1: the acquisition of gamma delta T cells；
The acquisition of 2:NK cell；
3: gamma delta T cells and NK mixing with cells cell object induced amplification co-culture；
The acquisition of 4:15-20 days gamma delta T cells and NK mixing with cells cell.
Wherein the gamma delta T cells are included the following steps:
(1) preparation of mononuclearcell: separation mononuclearcell contains 10vt% with the 50%-100% containing percent by volume
Cell is resuspended in the mixed culture medium of the RMPI 1640 and 0%-50%X-vivo15 of FBS or autoserum, be seeded in culture bottle or
It is cultivated in culture bag；
(2) zoledronic acid and 500~3000U/mL IL-2 that are 1-100 μM containing concentration the induction of gamma delta T cells: is added
It is added after mixed culture medium stimulated in vitro 4 days and contains 10~500ng/mL anti-human CD3Ab, 10~500ng/mL
Anti-human CD28Ab, 10~200ng/mL IL-15,10~200ng/mL IL-21,500~3000U/mL IL-2
Mixed culture medium carries out half amount and changes liquid, is placed in 37 DEG C, 5%CO2It is cultivated in incubator；
(3) it cultivates 2~3 days, it is well for later use to gamma delta T cells growth conditions.
Preferably, zoledronic acid concentration is 5 μM, anti-human CD3Ab concentration is 50ng/mL, anti-human
It is 50ng/mL, IL-21 concentration be 50ng/mL, IL-2 concentration is 1000U/mL that CD28Ab concentration, which is 50ng/mL, IL-15 concentration,.
Preferably, mononuclearcell derives from peripheral blood, Cord blood, marrow or inductive pluripotent stem cells (iPSC).
Other phosphoantigens also can be used in one embodiment instead of zoledronic acid, including isopentenyl pyrophosphate
(IPP), (E) -4- hydroxy-3-methyl-but-2-ene base pyrophosphate (HMB-PP), ethyl pyrophosphate (EPP), conversion
Ester (FPP), dimethyl-allyl phosphate (DMAP), dimethylallylpyrophosphate ester (DMAPP), ethyl-adenosine triphosphoric acid
Ester (EPPPA), geranylpyrophosphate ester (GPP), yak geranylpyrophosphate ester (GGPP), isopentenyl-adenosine pyrophosphate
(IPPPA), etherophosphoric acid (MEP), the biphosphonate containing nitrogen such as one ethyl ester of pyrophosphoric acid (MEPP).
Preferably, RMPI 1640 in a case study on implementation containing 10vt%FBS or autoserum in mixed culture medium
Ratio is 50vt%, and the ratio of X-vivo15 culture medium is 50vt%.
Wherein NK cell is included the following steps:
(1) mononuclearcell is separated；
(2) pass through the CD in immune sorting removal mononuclearcell3+T lymphocyte；
(3) NK cell culture serum-free cell culture medium and final concentration of 10-500ng/ml IL-15,10- is added
500ng/ml IL-12,10-500ng/ml IL-21,10-500ng/ml IL-18 and 500-2000U/ml IL-2 are seeded in carefully
Born of the same parents' culture bottle changes liquid after in vitro culture 2-5 days entirely, good to cell growth state.
Mononuclearcell described above is after acquiring peripheral blood by the sterile disposable heparin tube venipuncture of anticoagulant heparin,
The mononuclearcell for being obtained by Ficoll density gradient centrifugation or being acquired by single milling machine；Or from Cord blood, bone
The mononuclearcell that marrow and iPSCs induction differentiation obtain.
CD in the immune sorting removal mononuclearcell3+The immune sorting of immunomagnetic beads, film bubble can be used in T lymphocyte
The methods of sorting is immunized with flow cytometer.
The inoculum density of mononuclearcell after the removal CD3+T lymphocyte is 0.1-2 × 106Cells/ml, it is excellent
It is selected as 1 × 106cells/ml。
The concentration of interleukin-15 used is preferably 120-350ng/ml in the combination of cytokines.
The concentration of IL-12 used is preferably 100-300ng/ml in the combination of cytokines.
The concentration of interleukin-21 used is preferably 100-380ng/ml in the combination of cytokines.
The concentration of IL-18 used is preferably 100-300ng/ml in the combination of cytokines.
The concentration of proleulzin used is preferably 1000-1800U/ml in the combination of cytokines.
It is preferably the 4th day that the NK cell changes liquid number of days entirely, and cell concentration is preferably 1 × 106cells/ml。
It is the NK cell non-serum culture tune that required cell factor is expanded by adding cell containing NK that the NK cell, which changes liquid,
Whole NK cell concentration is to 1 × 106cells/ml。
Gamma delta T cells and the co-cultivation of NK mixing with cells cell object include the following steps:
(1) it takes the good gamma delta T cells of above-mentioned growth conditions appropriate, and is placed in culture bottle；
(2) it takes the good NK cell of above-mentioned growth conditions appropriate, and is placed in step 1 gamma delta T cells culture bottle；
(3) into culture bottle be added autoserum RMPI 1640 and X-vivo15 culture medium 1-2 days；1640 He of RMPI
The ratio of X-vivo15 is 1:0.5-5；
(4) 10-500ng/ml IL-15,10-500ng/ml IL-12,10- are added into Tissue Culture Flask within 2-3 days
The mixed culture medium of 500ng/ml IL-21,10-500ng/ml IL-18 and 500-2000U/ml IL-2 carry out half amount and change liquid,
It is placed in 37 DEG C, 5%CO2It is cultivated in incubator；
(5) it cultivates-the 18 day the 5th day, observes cell growth state daily, add the autoserum of factor-containing
RMPI 1640 and X-vivo15 culture medium maintain cell concentration 1 × 106Cells/ml is placed in saturated humidity, 37 DEG C, 5.0%
CO2Incubator continues to cultivate, and harvests cell when until reaching required cell quantity.Period, if cell volume is more than 240ml,
Sub-bottle culture is transferred to secondary culture in cell culture bags, 14-18 days harvest mixed cell cultures.
The gamma delta T cells inoculum concentration is 0.1-2 × 106Cells/ml, NK cell inoculation amount are 0.1-1 × 106cells/
ml。
The method of co-culturing, inducing amplification, first passing through stimulation induction mononuclearcell amplification is gamma delta T cells, is passed through simultaneously
Acquisition peripheral blood separation screening simultaneously stimulates induced amplification to go out NK cell, is trained afterwards by gamma delta T cells and the common induced activation of NK cell
It supports, while using a variety of amplification factors combination Co stituation induced amplification gamma delta T cells and NK cell, obtaining gamma delta T cells and NK
Cell co-cultures cell mixing, has the characteristics that quantity is big, amplification times are high, cytotoxicity is strong, and there is extraordinary clinic to answer
With value.
The raw materials used in the present invention and reagent are commercially available in addition to having specified otherwise.
Due to using above-mentioned technical solution, the beneficial effects of the present invention are: (1) the present invention provides a kind of gamma delta T-NK
Application of the cell co-cultured cell composition on NCI-H1975, mixing gamma delta T-NK cytotoxicity/activity is strong, to NCI-
The effect of H1975 is strong, almost can provide therapeutic scheme with 100% killing NCI-H1975 for NCI-H1975 type cancer and disease；
(2) co-culturing, inducing amplification method is easy to operate, and can get the gamma delta T cells and NK cell of massive amplification；(3) it and is stimulating
In the case that the factor lacks, incubation cell can mutually promote stimulating growth, shorten incubation time while obtaining a large amount of full
The medical cell amount of sufficient clinical demand, gamma delta T cells and NK cell massive amplification；(4) the cell combination that mode obtains is co-cultured
Object simplifies and individual cell progress immunization therapy is used for multiple times in clinic, reduces cost, simplify therapeutic process.
Detailed description of the invention:
Fig. 1 is amplification cultivation gamma delta T cells growth curve and amplification times；
Fig. 2 is amplification cultivation NK cell growth curve and amplification times；
Fig. 3 is amplification cultivation gamma delta T cells and NK cell growth curve and amplification times；
Fig. 4 is that gamma delta T cells, NK cell, gamma delta T cells and NK cell combine killing of the cell object to NCI-H1975 cell
Activity determination；
Fig. 5 is the growth inhibition effect of gamma delta T cells and NK mixing with cells cell object to cancer cell NCI-H1975 transplantable tumor.
Specific embodiment:
Below with reference to specific embodiment, technical scheme in the embodiment of the invention is clearly and completely described.It answers
Understand, described embodiments are some of the embodiments of the present invention, these embodiments are merely to illustrate the present invention rather than limit
The scope of the present invention processed.In addition, it should also be understood that, after reading the content taught by the present invention, those skilled in the art can be to this
Invention makes various changes or modifications, and these equivalent forms also fall within the scope of the appended claims of the present application.
In order to be easy to understand the technical means, the creative features, the aims and the efficiencies achieved by the present invention, tie below
Specific embodiment is closed, the present invention is further explained.
The acquisition of 1 gamma delta T cells of embodiment
The acquisition of gamma delta T cells separates mononuclearcell (PBMCs) from peripheral blood and expands gamma delta T cells:
(1) first 30 minutes unlatching Biohazard Safety Equipments are used；
(2) D-PBS is taken out from refrigerator using preceding, be placed at room temperature for 30 minutes；
(3) 30ml peripheral blood sample (anticoagulant heparin) is transferred to two sterile 50ml centrifuge tubes, every pipe 15ml, then
The sterile D-PBS of 22.5ml is added to every pipe, overturns centrifuge tube repeatedly, mixes well；
(4) two 50ml sterile centrifugation tubes separately are taken, is separately added into 15ml Ficoll-Paque Plus solution, then distinguishes
The blood (by drawing in two sterile tubes in step 3) after diluting in 24ml step 3 is slowly added, is formed and is layered, 20 DEG C,
400 × g is centrifuged 30 minutes；
(5) two 50ml centrifuge tubes in step 4 are put into Biohazard Safety Equipment, then sop up 15ml blood using 10ml suction pipe
Clear layer is fitted into a new sterile 50ml centrifuge tube, 56 DEG C of inactivations, 30 minutes stand-by (for preparing mixed culture medium)；
(6) leukocytic cream (PBMCs) in each 50ml centrifuge tube is drawn, a new 50ml sterile centrifugation is transferred to
Pipe；
(7) to step 6 equipped with being added the sterile PBS of its 3 times of volumes in the centrifuge tube of PBMCs cell suspension, and with sterile
Pipette mixes, and 20 DEG C, 400 × g, is centrifuged 10 minutes；
(8) supernatant is abandoned, the sterile PBS of 50ml is added, PBMC is slowly resuspended；
It (9) 20 DEG C, 400 × g, is centrifuged 10 minutes；
(10) mixed culture of the RMPI1640+50vt%X-vivo15 of 5ml 50vt% autoserum containing step 5 is added
Base mixes, and takes 10 μ l for counting；
(11) by taking the peripheral blood mononuclear cells (PBMCs) of half amount in step 10, certain volume is added and contains azoles
The mixed culture medium of phosphonic acids adjusts cell concentration to 1 × 106cells/ml；The PBMCs addition of the other half amount contains zoledronic acid
1640 culture medium of RPMI, adjustment cell concentration is to 1 × 106cells/ml；
(12) T-175 culture bottle culture cell is used；
(13) Tissue Culture Flask is placed in 5%CO2, carry out cell culture in 37 DEG C of cell incubators；
(14) on day 4 when, all cells are transferred in 50ml sterile centrifugation tube (20 DEG C, 400 × g, be centrifuged 5 minutes),
Replace amplification culture medium；Take half amount contain required amplification factor (anti-human CD3Ab, anti-human CD28Ab,
IL-15, IL-21 and IL-2) mixed culture medium of composition is added in empty Tissue Culture Flask, the cell culture medium after centrifugation
Supernatant is transferred in 50ml sterile centrifugation tube, takes half amount cell culture medium supernatant that cell is resuspended, respectively by the cell after resuspension
It is put into this step Tissue Culture Flask, 5%CO2, 37 DEG C continue to cultivate；
(15) in the 6th, 8,10,12,14,16 and 18 day replacement amplification culture medium.
The cell number of inoculating cell number and amplification cultivation is counted within the 0th, 4,6,8,10,12,14,16,18 and 20 day in culture,
Cell growth curve is made, as shown in Figure 1,30,000,000 cells of inoculation, expand 20 days, total number of cells can be completely full of about 26,000,000,000
Sufficient clinical application needs.It counts the 0th day, the 8th day, the 14th day and the 20th day, calculates gamma delta T cells amplification times, as shown in Figure 1.
The acquisition of embodiment 2NK cell
1, the separation of monocyte
1.1 under Biohazard Safety Equipment normal operating conditions, and 50ml sterile centrifugation tube is separately added into Ficoll-Paque Plus
Lymphocyte separation medium；
1.2 patient peripheral's whole blood and DPBS are uniformly diluted in proportion after be slowly injected into and separated in centrifuge tube medium size lymphocyte
Liquid liquid level upper layer；
It 1.320 DEG C, 400 × g, is centrifuged 30 minutes；
1.4 draw the plasma layer in separating pipe using aseptic straw, blood plasma are put into 50ml sterile centrifugation tube, 56 DEG C of water
It bathes 30 minutes and inactivates, 800g × centrifugation 10 minutes, upper plasma is transferred in new 50ml sterile centrifugation tube；
1.5 draw separating obtained mononuclearcell layer (PBMCs) loaded in 50ml sterile centrifugation tube；
1.6 are added DPBS, mix, 20 DEG C, 400 × g, are centrifuged 10 minutes, wash 1 time；
1.7 abandon supernatant, then all cells of 1.6 steps are resuspended into a 50ml sterile centrifugation tube with DPBS, mix, take
20 μ l cell suspensions, which are placed in 1.5ml EP pipe, to be counted.
2, NK cell expansion ex vivo-CD3+T cell removal
2.1, according to the count results of step 1.7, take out 5 × 105Cell is placed in 1.5ml EP pipe, for sorting preceding table
Type detection 20 DEG C of remaining cell, 400 × g, is centrifuged 10 minutes, then wash 1 time, abandons supernatant, with containing 0.5% human serum albumin
And the DPBS (0.5%HSA, 1mM EDTA, DPBS) of 1mM EDTA adjusts cell concentration to 1 × 108Cells/ml is transferred to
In the sterile streaming pipe of 5ml, EasysepTM Human CD3 Positive Selection Kit is added by 150 μ l/ml samples
Human CD3Positive Selection Cocktail II in II mixes, is placed at room temperature for 3min；
2.2 by the RapidSphereTM in EasysepTM Human CD3Positive Selection Kit II
50100 mix, and add in the streaming pipe of step 2.1 by 90 μ l/ml samples, mix, are placed at room temperature for 3min；
2.3 with 0.5%HSA is contained, and 1mM EDTA, DPBS are by the body of the cell suspension in the sterile streaming pipe of 5ml in step 2.2
Product polishing is mixed gently to 2.5ml；
The sterile streaming pipe of above-mentioned 5ml is placed in magnet and is stored at room temperature 3min by 2.4, picks up magnet, and cell is fallen in 15ml
In sterile centrifugation tube, takes 20 μ l cell suspensions to be placed in 1.5ml EP pipe and count.
3, NK cell expansion ex vivo-NK cell culture
3.1, according to 2.4 step count results, take out 5 × 105Cell is placed in 1.5ml EP pipe, is examined for phenotype after sorting
It surveys, remaining cell suspension is mended remaining cell volume to 14ml with L500 culture medium, is mixed, 20 DEG C, 400 × g, is centrifuged 5min；
3.2 abandon supernatant, 20 DEG C, 400 × g, are centrifuged 5min；
3.3 inhale abandoning supernatant, with SuperCultureTML500 (L500) culture medium containing 10% autoserum that cell is dense
Degree is adjusted to 1 × 106Cells/ml, IL-2, which is added, makes its final concentration of 1500IU/ml, and cell factor (IL-15, Il- is separately added
12, IL-21 and IL-18 final concentration is 200ng/ml), it mixes.
Cell is placed in 37 DEG C, saturated humidity, cultivated in 5.0%CO2 incubator by 3.4.
3.5 cultures the 4th day, cell are blown even, take 20 μ l cell suspensions to be placed in 1.5ml EP pipe, for counting.It is remaining
Cell is gone in 50ml sterile centrifugation tube, 20 DEG C, 400 × g, is centrifuged 5min；
3.6 abandon supernatant, cell are resuspended with the L500 culture medium containing 10% autoserum of Fresh, and it is dense to adjust cell
It spends to 1 × 106Cells/ml, while IL-2, which is added, makes its final concentration of 1500U/ml that cell factor (IL-15, Il- be added with another
12, IL-21 and IL-18 final concentration is 200ng/ml), it mixes.
Above-mentioned cell is placed in 37 DEG C, saturated humidity, 5.0%CO by 3.72Continue to cultivate in incubator.
3.8 cultures-the 21 day the 5th day, observe cell growth state daily, add the L500 culture medium of factor-containing
(if any enough blood plasma, can continue to 10% autologous plasma content) maintains cell concentration 1 × 106Cells/ml is placed in saturation
Humidity, 37 DEG C, 5.0%CO2Incubator continues to cultivate, and harvests cell when until reaching required cell quantity.Period, if cell body
Product then sub-bottle culture or is transferred to secondary culture in cell culture bags more than 240ml.
In the cell of the 0th, 4,6,8,10,12,14,16,18,20 and 22 day statistics inoculating cell number and amplification cultivation of culture
Number makes cell growth curve, as shown in Fig. 2, 15,600,000 cells of inoculation, expand 21 days, total number of cells can be complete of about 42,000,000,000
Full up foot clinical application needs.It counts the 0th day, the 6th day, the 14th day and the 22nd day, calculates NK cells expanded, it is seen that use
The method of the present invention can obtain a large amount of NK cell, as a result referring to fig. 2.
3 gamma delta T cells of embodiment and NK mixing with cells cell object co-culture
(1) the good gamma delta T cells 1-3ml of 3-10 days growth conditions is cultivated in Example 1, and is placed in culture bottle；
(2) the good NK cell 1-3ml of 3-10 days growth conditions is cultivated in Example 2, and it is thin to be placed in step 1 gamma delta T
In born of the same parents' culture bottle；
(3) into culture bottle be added autoserum RMPI 1640 and X-vivo15 culture medium 1-2 days；1640 He of RMPI
The ratio of X-vivo15 is 1:1；
(4) 1100ng/ml IL-15,100ng/ml IL-12,100ng/ml are added into Tissue Culture Flask in the 2-3 days
The mixed culture medium of IL-21,80ng/ml IL-18 and 500U/ml IL-2 carry out half amount and change liquid, are placed in 37 DEG C, 5%CO2Culture
It is cultivated in case；
(5) it cultivates-the 16 day the 5th day, observes cell growth state daily, add the autoserum of factor-containing
RMPI1640 and X-vivo15 culture medium maintains cell concentration 1 × 106Cells/ml is placed in saturated humidity, 37 DEG C, 5.0%CO2
Incubator continues to cultivate, and harvests cell when until reaching required cell quantity.Period, if cell volume is more than 240ml, sub-bottle
Cultivate or be transferred to secondary culture in cell culture bags, 17-18 days harvest mixed cell cultures.
In the cell number of the 0th, 4,6,8,10,12,14 and 16 day statistics inoculating cell number and amplification cultivation of culture, production is thin
Intracellular growth curve, as shown in figure 3,15,000,000 cell of NK cell inoculation, gamma delta T is inoculated with 20,000,000 cells, expands 16 days, cell is total
Number can be of about 110,000,000,000；Total cell number fully meets clinical application needs.As shown in figure 3, statistics the 0th day, the 8th day, the 12nd
It and the 16th day calculate gamma delta T cells and NK cells expanded.
The killing activity of 4 gamma delta T cells of embodiment and NK mixing with cells cell object to cancer cell NCI-H1975
Using 5 μM of CFSE to NCI-H1975 cell dyeing, by NK cell or gamma delta T cells or gamma delta T cells and NK cell
After 37 DEG C of incubation 4h, the PI dyestuff of 1 μ g/ml is added according to the ratio of 20:1 in cell mixing object or PBS and NCI-H1975 cell,
The cell of the bis- positives of CFSE+PI is dead cell, as shown in figure 4, gamma delta T cells and NK mixing with cells cell object can be significant increase
The killing activity of strong cancer cell, almost 100% killing SK-BR-3 cell.
And have above-described embodiment it can be concluded that, gamma delta T cells are being mixed after separating with NK cell, and two kinds of cells can be with
Proliferation of mutually promoting growth, and cell growth cycle is shortened, and in the case where stimulating factor lacks, gamma delta T cells and NK
Cell massive amplification, and cell mixing toxicity/activity is strong.
5 gamma delta T cells of embodiment and NK mixing with cells cell object make the growth inhibition of cancer cell NCI-H1975 transplantable tumor
With
By 5 × 106A NCI-H1975 cell inoculation has on hind leg in BALB/c nude mouse, grows to 100mm to tumour3
When, mouse is divided into four groups (every group 10), respectively by tail vein injection PBS, NK cell, gamma delta T cells, gamma delta T cells and
NK mixing with cells cell object, injection is primary weekly, and co-injection four times, tumor growth situation, as shown in figure 5, gamma delta T cells
The inhibition of the growth to NCI-H1975 cell transplantation tumor can be significantly increased with NK mixing with cells cell object.
The above shows and describes the basic principles and main features of the present invention and the advantages of the present invention.The technology of the industry
Personnel are it should be appreciated that the present invention is not limited to the above embodiments, and the above embodiments and description only describe this
The principle of invention, without departing from the spirit and scope of the present invention, various changes and improvements may be made to the invention, these changes
Change and improvement all fall within the protetion scope of the claimed invention.The claimed scope of the invention by appended claims and its
Equivalent thereof.
Claims (7)
1. a kind of application of cell composition on cancer cell NCI-H1975, it is characterised in that: gamma delta T cells and the combination of NK cell
Application of the object on cancer cell NCI-H1975.
2. application of the cell composition on cancer cell NCI-H1975 according to claim 1, it is characterised in that: gamma delta T is thin
Born of the same parents and NK cell proportion are 1:0.5-10.
3. application of the cell composition on cancer cell NCI-H1975 according to claim 2, it is characterised in that: gamma delta T is thin
Born of the same parents and NK cell the preparation method is as follows:
(1) acquisition of gamma delta T cells；
(2) acquisition of NK cell；
(3) gamma delta T cells and NK mixing with cells cell object induced amplification co-culture；
(4) acquisition of 15-20 days gamma delta T cells and NK mixing with cells cell.
4. application of the cell composition on cancer cell NCI-H1975 according to claim 3, it is characterised in that: gamma delta T is thin
The preparation method of born of the same parents are as follows:
(1) preparation of mononuclearcell: separation mononuclearcell contains 10vt%FBS with the 50%-100% containing percent by volume
Or cell is resuspended in the mixed culture medium of the RMPI 1640 and 0%-50%X-vivo15 of autoserum, is seeded in culture bottle or training
It supports and is cultivated in bag；
(2) mixing of the zoledronic acid and 500~3000U/mL IL-2 that are 1-100 μM containing concentration the induction of gamma delta T cells: is added
It is added after medium body external stimulus 4 days and contains 10~500ng/mL anti-human CD3Ab, 10~500ng/mL anti-
The mixing training of human CD28Ab, 10~200ng/mL IL-15,10~200ng/mL IL-21,500~3000U/mL IL-2
It supports half amount of base progress and changes liquid, be placed in 37 DEG C, 5%CO2It is cultivated in incubator；
(3) it cultivates 2~3 days, it is well for later use to gamma delta T cells growth conditions.
5. application of the cell composition on cancer cell NCI-H1975 according to claim 3, it is characterised in that: NK cell
Included the following steps: (1) separate mononuclearcell；
(2) pass through the CD in immune sorting removal mononuclearcell3+T lymphocyte；
(3) NK cell culture serum-free cell culture medium and final concentration of 10-500ng/ml IL-15,10-500ng/ is added
Ml IL-12,10-500ng/ml IL-21,10-500ng/ml IL-18 and 500-2000U/ml IL-2 are seeded in cell culture
Bottle changes liquid after in vitro culture 2-5 days entirely, good to cell growth state.
6. application of the cell composition on cancer cell NCI-H1975 according to claim 3, it is characterised in that: gamma delta T is thin
Born of the same parents and the co-cultivation of NK mixing with cells cell object include the following steps:
(1) it takes the good gamma delta T cells of growth conditions in individually culture appropriate, and is placed in culture bottle；
(2) it takes the good NK cell of growth conditions in individually culture appropriate, and is placed in above-mentioned steps (1) gamma delta T cells culture bottle
In；
(3) into culture bottle be added autoserum RMPI 1640 and X-vivo15 culture medium 1-2 days；
(4) 10-500ng/ml IL-15,10-500ng/ml IL-12,10-500ng/ml are added into Tissue Culture Flask within 2-3 days
The mixed culture medium of IL-21,10-500ng/ml IL-18 and 500-2000U/ml IL-2 carry out half amount and change liquid, be placed in 37 DEG C,
5%CO2It is cultivated in incubator；
(5) it cultivates-the 18 day the 5th day, observes cell growth state daily, add the RMPI of the autoserum of factor-containing
1640 and X-vivo15 culture medium maintains cell concentration 1 × 106Cells/ml is placed in saturated humidity, 37 DEG C, 5.0%CO2Culture
Case continues to cultivate, and harvests cell when until reaching required cell quantity；If cell volume is more than 240ml, sub-bottle culture or turn
Enter secondary culture in cell culture bags, 14-18 days harvest mixed cell cultures.
7. according to application of any one of the claim 4-6 cell composition on cancer cell NCI-H1975, feature exists
In: the ratio of RMPI 1640 and X-vivo15 is 1:0.5-5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910404770.5A CN110272870A (en) | 2019-05-16 | 2019-05-16 | A kind of application of cell composition on cancer cell NCI-H1975 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910404770.5A CN110272870A (en) | 2019-05-16 | 2019-05-16 | A kind of application of cell composition on cancer cell NCI-H1975 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110272870A true CN110272870A (en) | 2019-09-24 |
Family
ID=67960067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910404770.5A Pending CN110272870A (en) | 2019-05-16 | 2019-05-16 | A kind of application of cell composition on cancer cell NCI-H1975 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110272870A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101258238A (en) * | 2005-09-08 | 2008-09-03 | 迈世耐特股份公司 | Method for activation treatment of antigen-presenting cell |
| CN105296425A (en) * | 2015-12-07 | 2016-02-03 | 黑龙江天晴干细胞股份有限公司 | Multi-cell immune preparation for treating tumors and preparation method of multi-cell immune preparation |
| CN106222140A (en) * | 2016-08-04 | 2016-12-14 | 英普乐孚生物技术(上海)有限公司 | A kind of NK cell non-serum culture medium and compound method thereof |
| CN108220239A (en) * | 2018-01-30 | 2018-06-29 | 安徽瑞达健康产业有限公司 | A kind of composition for stimulating induction mononuclearcell amplification as gamma delta T cells and its application |
-
2019
- 2019-05-16 CN CN201910404770.5A patent/CN110272870A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101258238A (en) * | 2005-09-08 | 2008-09-03 | 迈世耐特股份公司 | Method for activation treatment of antigen-presenting cell |
| CN105296425A (en) * | 2015-12-07 | 2016-02-03 | 黑龙江天晴干细胞股份有限公司 | Multi-cell immune preparation for treating tumors and preparation method of multi-cell immune preparation |
| CN106222140A (en) * | 2016-08-04 | 2016-12-14 | 英普乐孚生物技术(上海)有限公司 | A kind of NK cell non-serum culture medium and compound method thereof |
| CN108220239A (en) * | 2018-01-30 | 2018-06-29 | 安徽瑞达健康产业有限公司 | A kind of composition for stimulating induction mononuclearcell amplification as gamma delta T cells and its application |
Non-Patent Citations (6)
| Title |
|---|
| AMUDHAN MANIAR ET AL.: ""Human γδ T lymphocytes induce robust NK cell–mediated antitumor cytotoxicity through CD137 engagement"", 《BLOOD》 * |
| AVI-HAI HOVAV: ""Human γδ T cells: rapid, stable and clonally reactive"", 《CELLULAR & MOLECULAR IMMUNOLOGY》 * |
| MIKI SAKAMOTO ET AL.: ""Adoptive Immunotherapy for Advanced Non-small Cell Lung Cancer Using Zoledronate-expanded γδT Cells: A Phase I Clinical Study"", 《J IMMUNOTHER》 * |
| 周忠海 等: ""唑来膦酸预处理的巨噬细胞诱导γδT细胞体外扩增的实验研究"", 《现代免疫学》 * |
| 周智锋 等: ""体外扩增对食管癌患者NK细胞表面受体表达及其抑瘤活性的影响"", 《中国肿瘤生物治疗杂志》 * |
| 姜孝新 等: ""NKG2D配体在肿瘤免疫中作用新进展"", 《肿瘤药学》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6010136B2 (en) | Method for producing natural killer cell, natural killer cell produced by the method, and composition for treating tumor and infectious disease containing the same | |
| CN108220239B (en) | A kind of stimulation induction mononuclearcell amplification is composition and its application of gamma delta T cells | |
| CN102268405B (en) | Method for auto NK (Natural Killer) cell in-vitro activation and amplification culture and special culture medium thereof | |
| US8679840B2 (en) | Compositions for the preparation of mature dendritic cells | |
| CN107922925A (en) | Method for natural killer cells amplification | |
| CN102137925B (en) | Method for simultaneous induction of CTL and [gamma][delta]t cell | |
| CN110283785A (en) | A kind of method that gamma delta T-NK cell co-cultures | |
| CN110564683A (en) | Method for co-culture induced amplification of gamma delta T cells and NK cells | |
| CN109810944A (en) | A kind of stabilization in vitro amplification high-purity, the method for high cytotoxic activity NK cell | |
| JP7295243B2 (en) | Human Vγ9Vδ2 T cell proliferation culture method and medium | |
| CN110511907A (en) | A kind of stabilization in vitro amplification high-purity, the method for high cytotoxic activity NK cell | |
| JP2022065102A (en) | Method for producing natural killer cells | |
| Gotti et al. | Optimization of therapeutic T cell expansion in G-Rex device and applicability to large-scale production for clinical use | |
| CN101182488A (en) | New use of mesenchyma stem cell | |
| CN110272871A (en) | A kind of stimulation induction mononuclearcell amplification is composition and its application of gamma delta T cells | |
| CN107502591B (en) | The iNKT methods for cell expansion and its application that a kind of concentration gradient rhIL-2 is relied on | |
| CN105838674A (en) | Method for inducing in-vitro expansion of CD8<+> regulatory T cells by immunosuppressants | |
| CN109957543A (en) | Utilize the method for Cord blood massive amplification Cord Blood Natural Killer Cells: Impact | |
| CN112662625A (en) | T cell culture medium and method for expanding and culturing T cells by using same | |
| CN114402065A (en) | Low density cell culture | |
| CN114438028B (en) | Method for in-vitro amplification of peripheral blood NK | |
| CN110862962A (en) | Method for culturing and amplifying NK cells in vitro by using gallic acid | |
| CN110272870A (en) | A kind of application of cell composition on cancer cell NCI-H1975 | |
| CN105018423A (en) | CIK cell culturing method | |
| CN110200996A (en) | A kind of application of cell composition on skin ulcer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190924 |